WEX Pharmaceuticals Inc.
TSX : WXI

WEX Pharmaceuticals Inc.

October 21, 2009 17:50 ET

Board Changes at WEX

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 21, 2009) - WEX Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI) announced today that two of its directors, Dr. Tom Du and Dr. John Sibert, had resigned from the Board.To fill the two vacancies, new directors were appointed at a Board meeting held yesterday.Joining the Board are Dr. Kee Hung Chu and Dr. Kean Meng Melvin Toh.

Dr. Chu is the Vice President and Chief Scientific Officer of CK Life Sciences Int'l., (Holdings) Inc. ("CKLS" or the "Group"). He is responsible for the technology and product development activities of the Group. Dr. Chu holds a Bachelor of Science from The Chinese University of Hong Kong, a Master of Science degree and a Doctor of Philosophy degree both from The University of California at Berkeley. He has over 20 years of experience in technology project management in the United States, Mainland China and Hong Kong.

Dr. Toh is Vice President, Pharmaceutical Development, of CKLS. He has an MBBS medical degree from The National University of Singapore and is registered with the Singapore Medical Council and General Medical Council, United Kingdom. He also holds a Master's degree in epidemiology from the University of London. Dr. Toh has over 15 years of experience in clinical medicine and pharmaceutical research and development in Asia and the United States.

Mr. Alan Yu, Chairman of the Board said, "I am very pleased to welcome the new directors. They bring a wealth of experience to the Board. I would also like, on the Board's behalf, to thank the outgoing directors for their outstanding contribution in the last few years."

About WEX Pharmaceuticals Inc.

WEX Pharmaceuticals Inc. is dedicated to the discovery, development, manufacture and commercialization of innovative drug products to treat pain. The Company's principal business strategy is to derive drugs from naturally occurring toxins and develop proprietary products for the global market.

Forward Looking Statements and Information

Certain statements herein may contain forward-looking statements and forward-looking information within the meaning of applicable securities laws. Forward-looking statements or information appear in a number of places and can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate" or "believes" or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements and information are subject to such risks, uncertainties and other factors which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or information. See our annual information form and our quarterly and annual management's discussion and analysis for additional information on risks and uncertainties relating to the forward-looking statements and information. There can be no assurance that forward-looking statements or information referenced herein will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements or information. Also, many of the factors are beyond the control of the Company. Accordingly, readers should not place undue reliance on forward-looking statements or information. All forward-looking statements and information made herein, are qualified by this cautionary statement.

Contact Information